Adalimumab - HUMIRA
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| D 2382/2022-ÚVN + 14-200/2022-1470 | 14. 11. 2022 | AbbVie s.r.o. | 52 600 891,20 | 47 818 992,00 | 52 600 891,20 | 47 818 992,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| D 2382/2022-ÚVN + 14-200/2022-1470 | KS VNOL_AdalHumira__anonymized.pdf | Smlouva | 01. 12. 2022 14:01 | Dokument není zavirovaný | |
| D 2382/2022-ÚVN + 14-200/2022-1470 | KS VNOL registr.pdf | Smlouva | 01. 12. 2022 14:01 | Dokument není zavirovaný | |
| Písemná zpráva AdalHumira signed 01122022.pdf | Písemná zpráva zadavatele | 01. 12. 2022 14:05 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| ViaPharma s.r.o. | Praha | |||||
| AbbVie s.r.o. | Praha |
Price Actually Paid in Each Year of Performance
| D 2382/2022-ÚVN + 14-200/2022-1470 | 2023 | 10 969 114,14 | 9 971 921,93 |
| D 2382/2022-ÚVN + 14-200/2022-1470 | 2022 | 2 109 969,02 | 1 918 153,64 |